Project Grant R42CA272132
Award Date
9/1/22
Completion Date
8/31/23
Dollars Obligated
$794K
Federal Agency
National Cancer Institute
Awardee
Sanicka, Inc. (N6X4B47G69J3)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award of $768,437.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to identify chemical compounds that inhibit the chromatin reader SGF29, which has been identified as a regulator of oncogenic transcription factors in acute myeloid leukemia (AML). The project will implement high-throughput screening assays to screen compound libraries and develop selective secondary/tertiary assays to validate hit compounds. Promising SGF29-inhibitory...
This $855,147 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will fund the development and evaluation of a novel "values elicitation tool" called PRIME (Preference Reporting to Improve Management and Experience) to improve treatment decision-making for older patients with acute myeloid leukemia (AML). The grant recipient, the University of North Carolina at Chapel Hill, will work under the guidance of a mentorship team to (1)...
This $349,887 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of an innovative artificial intelligence (AI) technology to select optimal cancer treatment options tailored to individual patients. The goal is to prolong patient life and reduce healthcare costs by avoiding initial treatment failures. The Research Foundation for the State University of New York (RF SUNY) is the prime...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant supports a 5-year research project to develop multimodal predictive models that leverage real-world data from sources like circulating tumor DNA sequencing, radiomics, and clinician notes to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The goal...
This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a biotechnology company based in San Diego, California, to conduct preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The research aims to develop an innovative therapeutic approach for these blood cancers, focusing on creating an antibody that can...
This $2,372,456 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports a collaborative effort led by the Sloan-Kettering Institute For Cancer Research to leverage observational (real-world) data to advance precision oncology. The key projects under this P01 program include: Overcoming methodological barriers in analyzing observational clinico-genomic data, with sub-awards to Dana-Farber Cancer Institute and University of California,...
This $811,500 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will fund the development of a comprehensive platform for patient-specific mechanistic tumor modeling. The key products and services to be delivered include: Merging bioinformatics software for single-cell and spatial multi-omics data analysis with an agent-based modeling framework (PhysiCell) to simulate cell movement and interactions in virtual tissue environments. This will be...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,995 to Cambium Oncology LLC to develop a novel immunotherapeutic drug called ANT308-FC3 Fusion for the treatment of acute myeloid leukemia (AML). The funding will support preclinical work to evaluate the drug's potency in activating human T cells, its anti-leukemia activity in mice, and its stability and pharmacokinetics (Phases 1 and 2). This research aims to advance ANT308-FC3...
This $321,304 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is supporting PDX Pharmaceuticals Inc., a minority-owned, woman-owned biotechnology company, in advancing the commercialization readiness of their nanoparticle-based immunotherapy called ARAC-02 for the treatment of non-small cell lung cancer (NSCLC). The key activities funded under this award include: 1) Protecting the intellectual property (IP) of the ARAC-02 product and the...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) has awarded a $387,630 Project Grant to the University of Colorado-Denver to support research on targeting therapy-resistant leukemia initiating cells (LICs) in acute myeloid leukemia (AML). The goal is to characterize distinct LIC subtypes and their vulnerabilities in order to design more effective and durable therapies for AML patients, particularly those with therapy-resistant or TP53-mutant disease. The project will...